Rare disease study opens door to new drug trials
NCT ID NCT00005909
First seen Nov 21, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This study aims to better understand alkaptonuria, a rare genetic disease that causes a pigment to build up in bones and tissues, leading to arthritis, fractures, and other problems. Researchers will evaluate up to 300 patients aged 2 and older with thorough medical tests every 2 to 3 years. The information gathered will help doctors advise patients and pave the way for future clinical trials of a new drug that blocks the harmful pigment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALKAPTONURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.